

1 December 2020

Notice of Final Date for Exercise of New Options

Minnesota, United States and Melbourne, Australia – 1 December 2020 – Osprey Medical Inc. (ASX:OSP) (**Osprey** or **the Company**) confirms that in accordance with the prospectus (**Prospectus**) issued for the 3 to 1 partially underwritten pro-rata renounceable entitlement offer announced by Osprey on 3 April 2020 (**Entitlement Offer**), the final exercise date for the unlisted options issued under the Entitlement Offer (**New Options**) is 15 February 2021. The New Options will expire at the end of 15 February 2021.

Optionholders who wish to exercise all or part of their New Options must ensure that Osprey receives a Notice of Exercise of Options form together with the payment of the relevant exercise monies on or before **5pm** on **15 February 2021** (Melbourne time).

To assist optionholders a “*Notice of Exercise of Options*” form is attached to this announcement and the form will also be available on Osprey’s website.

Osprey also confirms that in accordance with the terms of the New Options detailed in the Prospectus:

- each New Option on exercise will entitle its holder to subscribe for one CHES Depository Interest (**CDI**);
- the exercise price per New Option is \$0.014 or 1.4 cents;
- Pages 47 - 50 of the Prospectus set out the full terms and conditions of the New Options.

Osprey encourages optionholders who wish to exercise all or part of their New Options in February 2021 to submit their Notice of Exercise of Options form together with the payment of the relevant exercise monies prior to the 15 February 2021 exercise date.

Osprey will also update the market in late January 2021 to remind those optionholders intending to exercise their New Options of the impending final exercise date.

This announcement has been approved by the President & Chief Executive Officer, Mike McCormick

Contact details:

Investor relations

Leijie Li
Vesparum Capital
T: (61) 3 8582 4800

ospreymed@vesparum.com

Company

Doug Schoenberg
Vice President of Marketing
T: (952) 955 8230

dschoenberg@ospreymed.com

About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and

Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

NAME AND ADDRESS OF OPTIONHOLDER

SRN/HIN

Conversion Ratio: 1 for 1

Expiry Date: 15 February 2021

NOTICE OF EXERCISE OF OPTIONS
(Final Exercise Date 15 February 2021)

PLEASE COMPLETE BELOW

I/We apply to exercise the following number of Options and attach a cheque in Australian currency drawn on an Australian branch of a financial institution for the amount payable. Please allot me/us CHESS Depository Interests (CDIs) calculated on the basis of one (1) CDI for every one (1) Option which I/we exercise. I/We agree to accept such CDIs subject to the Certificate of Incorporation and Bylaws of Osprey Medical Inc.

A NUMBER OF OPTIONS EXERCISED

at A\$0.014 per
Option Exercised \$A

B TOTAL PAYMENT REQUIRED

You may exercise the Options wholly or in part by completing the Notice of Exercise Form. Please write in Box A the number of Options that you wish to exercise. If you do not indicate the number of Options you wish to Exercise, the Company will exercise as many Options as your accompanying cheque will pay for. However, the number of Options exercised will not exceed the number of Options you hold.

C PAYMENT OPTIONS - Choose one of the payment methods below.

Cheque Payment: Cheques must be drawn on an **Australian branch** of a financial institution in **Australian currency** and made payable to "Osprey Medical Inc." and crossed "Not Negotiable".

Cheque Number

BSB

Account Number

Electronic Funds Transfer:

Account Name: Osprey Medical Inc.

BSB: 013381

Account Number: 3175-70191

Payment Reference: please supply your SRN/HIN

D YOUR CONTACT DETAILS

Please provide your telephone number where you can be contacted during business hours regarding your Notice, if necessary.

Telephone Number

Contact Name (PRINT)

E HOW TO LODGE THE NOTICE OF EXERCISE OF OPTIONS

If paying by electronic funds transfer, the completed notice must be either mailed to the address below or emailed to: **brendan@casegovernance.com.au**

If paying by cheque, the completed notice must be forwarded with the accompanying payment, to the following address:

Osprey Medical Inc., PO Box 18355, Collins Street East, Melbourne VIC 8003.

Personal Information Collection Notification Statement: Link Group advises that personal information it holds about you (including your name, address, date of birth and details of the financial assets) is collected by Link Group organisations to administer your investment. Personal information is held on the public register in accordance with Chapter 2C of the *Corporations Act 2001*. Some or all of your personal information may be disclosed to contracted third parties, or related Link Group companies in Australia and overseas. Your information may also be disclosed to Australian government agencies, law enforcement agencies and regulators, or as required under other Australian law, contract, and court or tribunal order. For further details about our personal information handling practices, including how you may access and correct your personal information and raise privacy concerns, visit our website at www.linkmarketservices.com.au for a copy of the Link Group condensed privacy statement, or contact us by phone on +61 1800 502 355 (free call within Australia) 9am-5pm (Sydney time) Monday to Friday (excluding public holidays) to request a copy of our complete privacy policy.

